
Eisai Limited, the licence holder of AriceptŪ (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, announced today that the Court of Appeal has released its decision on the consequential issues arising from Court of Appeal's recent ruling that the process by which the National
Click here for full Story http://www.medicalnewstoday.com/articles/106983.php |